OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, announced that it will announce first quarter 2026 ...
The pitch, which Duran threw growing up until he ditched it in the minor leagues, averages 89.2 mph. But it is not to be ...
Taiwan-based Tripartite Therapeutics, Inc. (TTI) is positioning itself at the forefront of the global antibody-drug conjugate ...
Researchers discovered that polio and common cold viruses appear to rely on the same vulnerable mechanism to survive and ...
SIM0505/CDH6 ADC dose optimization initiated in gynecologic cancers SIM0505 Phase 1 dose escalation study data to be presented at ASCO 2026 LNCB74 Phase 1 dose escalation trial update planned in ...
We’ve entered the era of protein. Everything has protein — protein ice cream, protein oatmeal, protein Pop-Tarts®. In this ...